Last patient enrolled in pivotal study evaluating the efficacy of Modia in combination with sublingual buprenorphine/ naloxone for the treatment of opioid use disorder. Orexo AB
Orexo AB (publ.), announces the last participant has enrolled in the pivotal study of the digital therapeutic Modia as part of a clinician supervised medication-assisted treatment program for the treatment of opioid use disorder (OUD).
The randomized, open-label, parallel-group study is evaluating whether the use of Modia in combination with sublingual buprenorphine/naloxone background therapy is superior to sublingual buprenorphine/naloxone alone to reduce illicit opioid use. The study enrolled 437 participants at 35 sites across the US who voluntarily sought treatment for documented moderate to severe OUD.
The US opioid epidemic has claimed one million lives over the past two decades and is being driven by illicit opioids. The opioid epidemic has worsened during the COVID-19 pandemic. More Americans died of drug overdoses in 2021 than any previous year, including more than 80,000 deaths involving opioids.
Modia has been co-developed with GAIA, a leading global DTx company based in Hamburg, Germany, which has over two decades of industry leading DTx evidence development across multiple therapeutic categories.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.